Summary of ASHP/IDSA/SIDP vancomycin monitoring recommendations: A focus on osteomyelitis

Orthopedics

Volumn 32, Issue 7, 2009, Pages 499-

  Malloy, Katherine M ^a,b   Davis, George A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; GENTAMICIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BARTONELLA HENSELAE; BONE; CANDIDA ALBICANS; CHILD; CHILL; CLINICAL PRACTICE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG WITHDRAWAL; FEVER; FLUSHING; GRAM POSITIVE BACTERIUM; HUMAN; HYPOTENSION; INFECTION CONTROL; KIDNEY FUNCTION; LOADING DRUG DOSE; LONG TERM CARE; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OSTEOMYELITIS; OTOTOXICITY; PATIENT; PATIENT CARE; PATIENT MONITORING; PHARMACIST; PHLEBITIS; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TINNITUS;

HUMANS; OSTEOMYELITIS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS; UNITED STATES; VANCOMYCIN;

EID: 70349182417     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20090527-18     Document Type: Review

References (13)

1. Lew D, Waldvogel F. Osteomyelitis. N Engl J Med. 1997; 336(14):999-1007.
2. Elting L, Rubenstein E, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer. 1998; 83(12):2597-2607. (Pubitemid 29019582)
3. Rybak M, Rotschafer J, Moellering R, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health-System Pharm. 2009; 66(1):82-98.
4. Toma M, Smith K, Martin C, Rapp R. Pharmacokinetic considerations in the treatment of methicillin-resistant staphylococcus aureus osteomyelitis. Orthopedics. 2006; 29(6):497-502. (Pubitemid 43984650)
5. Rybak M. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(suppl 1):S35-S39.
6. Graziani A, Lawson L, Gibson G, Steinberg M, MacGregor R. Vancomycin concentrations in infected and non-infected human bone. Antimicrob Agents Chemother. 1988; 32(9):1320-1322. (Pubitemid 18215122)
7. Wysocki M, DeLatour F, Faurisson F. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460-2467 (Pubitemid 32801896)
8. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004; 29(4):351-357. (Pubitemid 39062165)
9. Miles M, Li L, Lakkis H, Youngblood J, McGinnis P. Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther Drug Monit. 1997; 19(3):265-270. (Pubitemid 28053479)
10. Thomas M, Steele R. Monitoring serum vancomycin concentrations in children: is it necessary? Pediatr Infect Dis J. 1998; 17(4):351-353.
11. Hidayat L, Hsu D, Quist R, Shriner K, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166(19):2138-2144. (Pubitemid 44631403)
12. Tenover F, Moellering R. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureus. Clin Infect Dis. 2007; 44(9):1208-1215. (Pubitemid 46651246)
13. Rybak M, Albrecht L, Boike S, Chandrasekar P. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25(4):679-687.